Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
93 hedge funds and large institutions have $204M invested in Harpoon Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 33 reducing their positions, and 14 closing their positions.
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
9% more funds holding
Funds holding: 85 → 93 (+8)
4% less call options, than puts
Call options by funds: $659K | Put options by funds: $687K
9.21% less ownership
Funds ownership: 88.19% → 78.98% (-9.2%)
33% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 33
43% less capital invested
Capital invested by funds: $357M → $204M (-$153M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.93M |
| 2 |
Two Sigma Investments
New York
|
+$4.09M |
| 3 |
Renaissance Technologies
New York
|
+$4.03M |
| 4 |
Two Sigma Advisers
New York
|
+$3.79M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.1M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$9.88M |
| 3 |
State Street
Boston,
Massachusetts
|
-$9.5M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$8.05M |
| 5 |
VA
VR Adviser
New York
|
-$7.1M |
HARP Hedge Fund Activity: Q3 2021 in Review
93 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q3 2021, worth a combined $204M — down 43% from $357M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new HARP positions and 14 closed out — a net gain of 8 holders — while 22 added to existing stakes and 33 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.93M. The largest seller was Logos Global Management, exiting entirely with an estimated $11.1M sold.
- 93 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q3 2021, up from 85 in Q2 2021.
- Funds reported $204M of Harpoon Therapeutics, Inc. Common Stock stock for Q3 2021, down 43% quarter-over-quarter.
- 22 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q3 2021 and 14 closed out, a net change of +8 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q3 2021 was Millennium Management, an estimated $5.93M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q3 2021 was Logos Global Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2021.